Professor Paul Martin
BA (Hons), MSc, DPhil
Department of Sociological Studies
Professor of Sociology
+44 114 222 6414
Full contact details
Department of Sociological Studies
Paul works at the interface of science and technology studies (STS) and medical sociology. He joined the Department in March 2012 to take up the position of Chair in the Sociology of Science and Technology, and Director of Research. He was Head of Department from April 2014-December 2016.
He has a first training in biology with a BA Zoology from the University of Cambridge. He won an MRC PhD studentship to undertake biomedical research at the Mammalian Development Unit at University College London, but his scientific career ended after he suffered a very serious head injury in a road traffic accident.
Paul then worked for a number of years in the voluntary sector as a campaigner and policy analyst for the group Health Rights.
He returned to academia after taking an MSc in Sociology (social policy) at Southbank University and completed a DPhil part-time at SPRU at the University of Sussex. His PhD thesis was a historical sociology of the development of gene therapy in the USA.
Paul worked at SPRU as a Research Fellow on a series of EU projects related to innovation in the bio/pharmaceutical industry, science policy and the regulation of emerging medical technologies
In 1999 he moved to the University of Nottingham and helped establish the Institute for Science and Society (ISS) as one of Europe’s leading centres in STS with a strong commitment to supporting the career development of postgraduate students and early career researchers. He was Director of ISS from 2009-2012 until he moved to Sheffield.
- Research interests
Paul has a strong track record of high quality empirical research, as well as research leadership and project management. Over the course of his career he has raised over £2.6M of external funding as Principal Investigator and held seven major awards (worth > £100k) from the ESRC, Wellcome Trust, Leverhulme Trust, and European Union. He has published ~ 50 peer reviewed articles in leading national and international journals.
Currently Paul’s research interests are:
- The development of epigenetics and the role of science in (social) policy;
- Novel biosocial concepts and methods in the social sciences;
- What it means to be human in the 21st Century;
- The clinical and commercial development of genomics and personalised medicine;
- Responsible Research and Innovation.
Paul is currently Principal Investigator on a Leverhulme Trust funded grant; How Does Inequality get Under the Skin? Epigenetics, health disparities and the making of social policy (2014-18, £215,000).
This is studying the development of the emerging science of epigenetics as a means of better understanding the link between deprivation and inequalities in health, and how this new knowledge is being used to inform public policy.
The project has a strong focus on providing a sociological understanding of how this new multidisciplinary field is being constructed and the role of epigenetics in providing accounts of the biological embodiment of social and environmental experience.
His work on epigenetics is part of a broader exploration of the changing relationship between biology and society, and the rise of new ‘biosocial’ approaches to understanding questions of health, behaviour and social interaction.
In particular, Paul is interested in how ideas of society and ‘the social’ are used in the biological sciences and how novel biosocial methods might be applied to social science research. In future, he is looking to extend this strand of work to critically investigate how new biological knowledge is changing how we understand what is means to be human.
To help achieve this, Paul is working closely with Dan Goodley and Kirsty Liddiard (Education) and Warren Pearce and Stevie deSaille (Sociological Studies) to establish a major new multidisciplinary Institute for the Study of the Human (iHuman) iHuman draws on expertise from across the social sciences, humanities and STEM disciplines, and brings together academics, community groups and third sector organisations.
It promotes risky conversations between and across disciplines and does this primarily through a number of externally funded research projects.
Another strand of ongoing research concerns the clinical and commercial development of emerging biotechnologies. This builds on his previous research on genomic medicine, pharmacogenetics, regenerative medicine, synthetic biology and gene therapy.
Paul is currently undertaking preliminary research and preparing funding applications on the development of gene editing technology (with Ilke Turmendag, Newcastle).
He has contributed to policy debates in this area and has been invited to an OECD Expert Meeting on Gene Editing in Berlin in July 2017.
Before leaving Nottingham Paul was awarded a £1.7M Leverhulme Trust programme grant on Making Science Public: Opportunities and Challenges. He was initially PI on this major five-year grant, but this role was taken over by Brigitte Nerlich in December 2011, who successfully delivered an outstanding programme of research.
As part of this, Paul recently completed a project (with Stevie deSaille) on policymakers and activist concepts of responsible research and innovation (RRI). He currently chairs the University of Sheffield working group on RRI.
- Spatiotemporal readiness is key to preparing regenerative medicine for the clinic. Regenerative Medicine, 16(3), 229-235.
- The social underpinnings of mental distress in the time of COVID-19 – time for urgent action. Wellcome Open Research, 5. View this article in WRRO
- Genome editing: the dynamics of continuity, convergence and change in the engineering of life. New Genetics and Society. View this article in WRRO
- Regenerative medicine in India: trends and challenges in innovation and regulation. Regenerative Medicine.
- Have we seen the geneticisation of society? Expectations and evidence. Sociology of Health and Illness. View this article in WRRO
- Five Rules of Thumb for Post-ELSI Interdisciplinary Collaborations. Journal of Responsible Innovation, 3(1), 73-80. View this article in WRRO
- The biosocial: sociological themes and issues. The Sociological Review Mongraphs, 64(1), 7-25. View this article in WRRO
- Commercialising neurofutures: Promissory economies, value creation and the making of a new industry. BioSocieties, 10(4), 422-443.
- The changing brain: Neuroscience and the enduring import of everyday experience. Public Understanding of Science, 24(7), 878-892. View this article in WRRO
- Pharmaceuticals and society: Power, promises and prospects. Social Science and Medicine, 131, 193-198.
- View this article in WRRO Taking Roles in Interdisciplinary Collaborations: Reflections on Working in Post-ELSI Spaces in the UK Synthetic Biology Community. Science and Technology Studies, 28(3), 3-25.
- Mapping the new molecular landscape: Social dimensions of epigenetics. New Genetics and Society, 32(4), 429-447.
- Constructing notions of healthcare productivity: The call for a new professionalism?. Sociology of Health and Illness.
- Constituting Neurologic Subjects: Neuroscience, Subjectivity, and the Mundane Significance of the Brain. Subjectivity: international journal of critical psychology, 4(3), 346-365.
- The pharmaceuticalisation of society? A framework for analysis. Sociology of Health and Illness, 33(5), 710-725.
- Evolving sociological analyses of 'Pharmaceuticalisation': A reply to Abraham. Sociology of Health and Illness, 33(5), 729-730.
- Medical Sociology and Genetics, 511-529.
- Modafinil in the media: metaphors, medicalisation and the body.. Soc Sci Med, 68(3), 487-495.
- Drug induced cognitive enhancement and society. Frontiers in Neuroscience, 3(1).
- Industry perceptions of barriers to commercialization of regenerative medicine products in the UK. Regenerative Medicine, 4(4), 549-559.
- The role of social scientists in synthetic biology. EMBO Reports, 10(3), 201-204.
- Stem cells for enhancing recovery after stroke: A review. International Journal of Stroke, 4(2), 101-110.
- Synthetic biology and the public. Science and Public Affairs, 23-23.
- An interdisciplinary perspective on the impact of genomics on the meaning of 'race', and the future role of racial categories in biomedical research. NTM Journal of History of Sciences, Technology, and Medicine, 16, 378-386.
- A genetic future for coronary heart disease?. Sociol Health Illn, 30(3), 380-395.
- From bedside to bench? Communities of Promise, Translational Research and the Making of Blood Stem Cells. Science As Culture, 17(1), 29-41.
- Regenerative medicine-A new industry ~ remedi ~ A grand challenge. European Cells and Materials, 16(SUPPL. 3), 1.
- Capitalizing hope: The commercial development of umbilical cord blood stem cell banking. New Genetics and Society, 27(2), 127-143.
- The standardization of race and ethnicity in biomedical science editorials and UK biobanks. Social Studies of Science, 38(3), 407-423.
- Flaws in the U.S. food and drug administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients. Journal of Law, Medicine and Ethics, 36(3), 449-457.
- Social inclusivity vs analytical acuity? A qualitative study of UK researchers regarding the inclusion of minority ethnic groups in biobanks. Medical Law International, 9(2), 169-190.
- Genotyping the future: Scientists' expectations about race/ethnicity after BiDil. Journal of Law, Medicine and Ethics, 36(3), 464-470.
- The myth of the biotech revolution: An assessment of technological, clinical and organisational change. Research Policy, 36(4), 566-589.
- Commercial development of stem cell technology: lessons from the past, strategies for the future.. Regen Med, 1(6), 801-807.
- Beyond the next generation of therapeutic proteins. Bio Tech International, 18(5), 17-19.
- Biobanks, national identity and imagined communities: The case of UK biobank. Science as Culture, 15(3), 237-251.
- Can Science Alone Improve the Measurement and Communication of Race and Ethnicity in Genetic Research? Exploring the Strategies Proposed by 'Nature Genetics'. BioSocieties, 1(3), 313-324.
- The Promissory Pasts of Blood Stem Cells. BioSocieties, 1(3), 329-348.
- The promise of pharmacogenetics: assessing the prospects for disease and patient stratification. Studies in History and Philosophy of Science Part C :Studies in History and Philosophy of Biological and Biomedical Sciences, 37(3), 583-601.
- Putting pharmacogenetics into practice. Nature Biotechnology, 24(4), 403-410.
- Role of pharmacogenetics in the use of CNS drugs: From drug pipeline to primary care?. Expert Review of Neurotherapeutics, 6(12), 1765-1767.
- The paradox of race/ethnicity. Critical Public Health, 15(1), 77-78.
- Tailored medicine: Whom will it fit? The ethics of patient and disease stratification. Bioethics, 18(4), 322-343.
- Genetic and genomic discourses at the dawn of the 21st century. Discourse and Society, 15(4), 363-368.
- The myth of the biotech revolution. Trends in Biotechnology, 22(11), 564-569.
- Integrating pharmacogenetics into society: In search of a model. Nature Reviews Genetics, 5(9), 663-669.
- The drugs don't work: expectations and the shaping of pharmacogenetics.. Soc Stud Sci, 33(3), 327-364.
- Regulating the commercial development of genetic testing in the UK: Problems, possibilities and policy. Critical Social Policy, 23(2), 186-207.
- Genetic governance: The risks, oversight and regulation of genetic databases in the uk. New Genetics and Society, 20(2), 157-183.
- Industry update.. J Gene Med, 2(4), 301-302.
- RCT - RIP, or, can the pharmaceutical industry survive the genomic revolution?. Journal of Health Services Research and Policy, 5(2), 67-68.
- The use of large biological sample collections genetics research: Issues for public policy. New Genetics and Society, 19(2), 165-191.
- Safeguards for research using large scale DNA collections. British Medical Journal, 321(7269), 1146-1149.
- Genes as drugs: the social shaping of gene therapy and the reconstruction of genetic disease. Sociology of Health and Illness, 21(5), 517-538.
- The Commercial Development of Gene Therapy in Europe and the USA. Human Gene Therapy, 9(1), 87-114.
- Bridging the ‘commercialisation gap’ in Europe. Gene Therapy, 4(9), 881-882.
- Royaume-Uni : la locomotive de I'Europe. Biofutur, 1997(163), 31-33.
- Des essais cliniques à foison. Biofutur, 1997(163), 12-18.
- The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine. Regulation & Governance.
- From Eugenics to Therapeutics: The Impact of Opposition on the Development of Gene Therapy in the USA, The Social Management of Genetic Engineering (pp. 139-157). Routledge
- Monstrous regiment versus Monsters Inc.: Competing imaginaries of science and social order in Responsible (Research and) Innovation In Nerlich B, Hartley S, Raman S & Smith A (Ed.), Science and the politics of openness: Here be monsters Manchester: Manchester University Press.
- The use of large biological sample collections in genetics research: Issues for public policy, Reconfiguring Nature (2004): Issues and Debates in the New Genetics (pp. 96-132).
- Governing the Stem Cell Sector in India, Stem Cells in Clinical Applications (pp. 247-262). Springer International Publishing
- 'Race' as a social construction in genetics In Schramm K, Skinner D & Rottenburg R (Ed.), Identity Politics and the New Genetics: Re/Creating Categories of Difference and Belonging (pp. 30-52). Berghahn
- Neuroscience and medicalisation: Sociological reflections on memory, medicine and the brain In Pickersgill M & Van Keulen, I (Ed.), Sociological Reflections on the Neurosciences (pp. 231-254).
- Pharmaceutical cognitive enhancement: Interrogating the ethics, addressing the issues, Augmenting Cognition (pp. 179-192).
- Is the biotechnology revolution a myth?, Comprehensive Medicinal Chemistry II (pp. 591-613).
- Routledge Handbook of Genomics, Health and Society Routledge
- Medicalization and pharmaceuticalization at the intersections: A commentary on Bell and Figert (2012). Social Science & Medicine, 75(12), 2129-2130.
- Risks and benefits may turn out to be finely balanced. Nature, 457(7229), 532-532.
- Teaching activities
- SCS1017 Science, Technology and Society
- SCS3034 What it means to be Human